Vigilant Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $687K | Buy |
10,749
+900
| +9% | +$60.4K | 0.05% | 74 |
|
|
2023
Q1 | $683K | Buy |
9,849
+450
| +5% | +$31.7K | 0.06% | 69 |
|
|
2022
Q4 | $676K | Hold |
9,399
| – | – | 0.06% | 73 |
|
|
2022
Q3 | $668K | Sell |
9,399
-181
| -2% | -$13.1K | 0.06% | 70 |
|
|
2022
Q2 | $738K | Buy |
9,580
+181
| +2% | +$13.8K | 0.06% | 69 |
|
|
2022
Q1 | $686K | Hold |
9,399
| – | – | 0.05% | 78 |
|
|
2021
Q4 | $586K | Buy |
9,399
+7,478
| +389% | +$439K | 0.04% | 100 |
|
|
2021
Q3 | $114K | Buy |
1,921
+333
| +21% | +$21.9K | 0.01% | 196 |
|
|
2021
Q2 | $106K | Buy |
1,588
+39
| +3% | +$2.54K | 0.01% | 204 |
|
|
2021
Q1 | $98K | Sell |
1,549
-1,416
| -48% | -$88.1K | 0.01% | 194 |
|
|
2020
Q4 | $184K | Sell |
2,965
-334
| -10% | -$20.5K | 0.02% | 141 |
|
|
2020
Q3 | $199K | Buy |
3,299
+361
| +12% | +$21.7K | 0.02% | 134 |
|
|
2020
Q2 | $173K | Hold |
2,938
| – | – | 0.02% | 137 |
|
|
2020
Q1 | $164K | Sell |
2,938
-2,803
| -49% | -$171K | 0.02% | 124 |
|
|
2019
Q4 | $369K | Sell |
5,741
-297
| -5% | -$17K | 0.04% | 94 |
|
|
2019
Q3 | $306K | Hold |
6,038
| – | – | 0.04% | 96 |
|
|
2019
Q2 | $274K | Sell |
6,038
-2,735
| -31% | -$127K | 0.04% | 101 |
|
|
2019
Q1 | $419K | Sell |
8,773
-1,340
| -13% | -$66.8K | 0.06% | 82 |
|
|
2018
Q4 | $526K | Buy |
10,113
+440
| +5% | +$23.6K | 0.08% | 75 |
|
|
2018
Q3 | $600K | Sell |
9,673
-600
| -6% | -$35.6K | 0.08% | 76 |
|
|
2018
Q2 | $569K | Sell |
10,273
-1,605
| -14% | -$86.7K | 0.08% | 70 |
|
|
2018
Q1 | $751K | Sell |
11,878
-980
| -8% | -$63K | 0.11% | 67 |
|
|
2017
Q4 | $788K | Buy |
12,858
+3,594
| +39% | +$225K | 0.1% | 81 |
|
|
2017
Q3 | $590K | Buy |
9,264
+377
| +4% | +$22K | 0.09% | 78 |
|
|
2017
Q2 | $495K | Hold |
8,887
| – | – | 0.08% | 79 |
|
|
2017
Q1 | $483K | Sell |
8,887
-825
| -8% | -$45.3K | 0.08% | 78 |
|
|
2016
Q4 | $568K | Hold |
9,712
| – | – | 0.1% | 78 |
|
|
2016
Q3 | $524K | Sell |
9,712
-872
| -8% | -$56K | 0.09% | 79 |
|
|
2016
Q2 | $778K | Buy |
10,584
+1,275
| +14% | +$90.1K | 0.15% | 68 |
|
|
2016
Q1 | $595K | Hold |
9,309
| – | – | 0.12% | 69 |
|
|
2015
Q4 | $640K | Buy |
9,309
+439
| +5% | +$29K | 0.13% | 71 |
|
|
2015
Q3 | $525K | Buy |
8,870
+500
| +6% | +$31.7K | 0.11% | 76 |
|
|
2015
Q2 | $557K | Hold |
8,370
| – | – | 0.1% | 82 |
|
|
2015
Q1 | $540K | Hold |
8,370
| – | – | 0.1% | 80 |
|
|
2014
Q4 | $494K | Buy |
8,370
+3,540
| +73% | +$200K | 0.1% | 84 |
|
|
2014
Q3 | $247K | Hold |
4,830
| – | – | 0.05% | 88 |
|
|
2014
Q2 | $234K | Hold |
4,830
| – | – | 0.05% | 84 |
|
|
2014
Q1 | $251K | Buy |
4,830
+460
| +11% | +$24.5K | 0.06% | 80 |
|
|
2013
Q4 | $232K | Hold |
4,370
| – | – | 0.06% | 93 |
|
|
2013
Q3 | $202K | Hold |
4,370
| – | – | 0.06% | 83 |
|
|
2013
Q2 | $195K | Buy |
+4,370
| New | +$190K | 0.06% | 86 |
|
Other funds holding BMY
Vigilant Capital Management's BMY Position: Q2 2023 in Review
Vigilant Capital Management increased its Bristol-Myers Squibb (BMY) stake by 9.1% in Q2 2023, buying an estimated $60.4K and bringing the position to 10,749 shares worth $687K. The position accounts for 0.05% of the portfolio, ranked #74.
Vigilant Capital Management first reported a position in BMY in Q2 2013 and has held it in 41 quarters since. The position peaked at $788K in Q4 2017. 2,480 funds tracked by Wall St. Rank hold BMY as of Q2 2023.
- Vigilant Capital Management held 10,749 shares of Bristol-Myers Squibb worth $687K as of Q2 2023.
- Vigilant Capital Management bought 900 Bristol-Myers Squibb shares in Q2 2023, an estimated $60.4K.
- Bristol-Myers Squibb made up 0.05% of Vigilant Capital Management's portfolio in Q2 2023, its #74 holding.
- Vigilant Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 41 quarters since.
- Vigilant Capital Management's Bristol-Myers Squibb position peaked at $788K in Q4 2017.
- 2,480 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.
Based on Vigilant Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.